AEON Biopharma

Develops ABP-450, a botulinum toxin type A candidate proposed as a biosimilar to Botox for therapeutic uses rather than cosmetic uses. The intended label covers chronic migraine, movement disorders, bladder conditions, limb spasticity and excessive underarm sweating, subject to FDA approval. Development management is based in Irvine, California, while the license covers therapeutic territories across the United States, Europe, Canada, Australia, Russia, the Commonwealth of Independent States and South Africa.

Operates as an outsourced developer, relying on Daewoong Pharmaceutical as the sole manufacturer and supplier and on contract research organizations, laboratories, investigators and consultants for clinical execution. Its model depends on a biosimilar approval path, analytical-similarity evidence, FDA requirements, and therapeutic-use rights under its Daewoong and Medytox agreements. No product is approved for therapeutic sale and no product revenue has been generated.